View on Pubmed.gov 36536643 | View on doi.org 10.2147/JIR.S38...
Special Focus on the Cellular Anti-Inflammatory Effects of Several Micro-Immunotherapy Formulations: Considerations Regarding Intestinal-, Immune-Axis-Related- and Neuronal-Inflammation Contexts.
- Preclinical Research Department, Labo'Life France, Nantes, France.
Abstract
Introduction
Chronic inflammation is a pernicious underlying status, well-known for its contribution to the progressive development of various diseases. In this regard, Micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) and ultra-low doses (ULD) of immune regulators in their formulations. In particular, as both IL-1β and TNF-α are often used at ULD in MI medicines (MIM), a special emphasis has been made on formulations that include these factors in their compositions.
Methods
Several in vitro models have been employed in order to assess the effects of two unitary MIM consisting of ULD of IL-1β and TNF-α (u-MIM-1 and u-MIM-2, respectively), and four complex MIM (c-MIM-1, -2, -3 and -4) characterized by the presence of ULD of IL-1β and TNF-α amongst other factors. Thus, we first investigated the anti-inflammatory effects of u-MIM-1 and u-MIM-2 in a model of inflamed colon carcinoma cells. In addition, the anti-inflammatory potential of c-MIM-1, -2, -3 and -4, was assessed in in vitro models of intestinal and neuronal inflammation.
Results
The results revealed that u-MIM-1 and u-MIM-2 both induced a slight decrease in the levels of IL-1β and TNF-α transcripts. Regarding the c-MIMs' effects, c-MIM-1 displayed the capability to restore the altered transepithelial electrical resistance in inflamed-HCoEpiC cells. Moreover, c-MIM-1 also slightly increased the expression of the junction-related protein claudin-1, both at the mRNA and protein levels. In addition, our in vitro investigations on c-MIM-2 and c-MIM-3 revealed their immune-modulatory effects in LPS-inflamed human monocytes, macrophages, and granulocytes, on the secretion of cytokines such as TNF-α, PGE2, and IL-6. Finally, c-MIM-4 restored the cell viability of LPS/IFN-γ-inflamed rat cortical neurons, while reducing the secretion of TNF-α in rat glial cells.
Discussion
Our results shed the light on the potential role of these MIM formulations in managing several chronic inflammation-related conditions.
References
Crit Rev Immunol. 2012;32(1):23-63
Immunity. 2017 Jun 20;46(6):927-942
Immunity. 2008 Apr;28(4):468-76
Int J Mol Sci. 2022 Feb 19;23(4):
Cited by 6 citations (total)
Journal Article
Understanding the Mode of Action of a Micro-Immunotherapy Formulation: Pre-Clinical Evidence from the Study of 2LEBV Active Ingredients.
Electronic publication date January 23, 2024
Camille Jacques [...] Ilaria Floris et al.
BACKGROUND
Epstein-Barr virus (EBV) is often kept silent and asymptomatic; however, its reactivation induces a chronic and/or recurrent infection that is...
Journal Article
Actives from the Micro-Immunotherapy Medicine 2LMIREG Reduce the Expression of Cytokines and Immune-Related Markers Including Interleukin-2 and HLA-II While Modulating Oxidative Stress and Mitochondrial Function.
Electronic publication date February 26, 2024
Camille Jacques [...] Ilaria Floris et al.
Introduction
Micro-immunotherapy (MI) is a therapeutic option employing low doses (LD) and ultra-low doses (ULD) of cytokines and immune factors to...
Conflict of interest statement
The authors declared the following conflicts of interest with respect to the research, authorship, and/or publication of this article, Camille Jacques and Ilaria Floris work for Labo’Life France, the company service provider of Labo’Life, which is specialized in preclinical research and regulatory affairs. This professional relationship does not imply any misconduct on the part of the authors.
MeSH
- •
- •
Specialties
- •
- •
- •
- •
- •
Copyright
© 2022 Jacques and Floris.